Literature DB >> 3510249

Two major classes of mitogen-reactive B lymphocytes defined by life span.

A A Freitas, B Rocha, A A Coutinho.   

Abstract

The relative numbers of short- and long-lived mitogen-reactive B cells in the peripheral pool were evaluated by studying the decay of lipopolysaccharide (LPS)-reactive B lymphocytes in LPS nonresponder, histocompatible hosts for periods of up to 3 wk after cell transfer. The results obtained demonstrate the existence of two major classes of mitogen-reactive B cells defined by life span. The "short-lived" cell component comprises about 80 to 90% of the reactive cells and decays with a life expectancy of 18 to 24 hr. The long-lived cell component, with life expectancies of 10 to 20 days, comprises about 10 to 20% of the reactive cells and is preferentially enriched in circulating B cells. The present ratio for short- and long-lived B cells implies a highly dynamic state for the immune system which must be advantageous in the selection of available repertoires.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510249

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Ability of spleen, peritoneal cavity, and lymph node B cells to reconstitute serum immunoglobulin in SCID mice.

Authors:  J Riggs; R Stowers
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

2.  The bulk of the peripheral B-cell pool in mice is stable and not rapidly renewed from the bone marrow.

Authors:  I Förster; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

3.  Mature murine B and T cells transferred to SCID mice can survive indefinitely and many maintain a virgin phenotype.

Authors:  J Sprent; M Schaefer; M Hurd; C D Surh; Y Ron
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

4.  Cross-linking of membrane immunoglobulin D, in the absence of T cell help, kills mature B cells in vivo.

Authors:  F D Finkelman; J M Holmes; O I Dukhanina; S C Morris
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.